IN2014CN00408A - - Google Patents

Info

Publication number
IN2014CN00408A
IN2014CN00408A IN408CHN2014A IN2014CN00408A IN 2014CN00408 A IN2014CN00408 A IN 2014CN00408A IN 408CHN2014 A IN408CHN2014 A IN 408CHN2014A IN 2014CN00408 A IN2014CN00408 A IN 2014CN00408A
Authority
IN
India
Prior art keywords
formula
relates
pyridine ring
present
membered fused
Prior art date
Application number
Other languages
English (en)
Inventor
Tjeerd A Barf
Christiaan Gerardus Johannes Maria Jans
De Adrianus Petrus Antonius Man
Arthur A Oubrie
Hans C A Raaijmakers
Johannes Bernardus Maria Rewinkel
Jan Gerard Sterrenburg
Jacobus C H M Wijkmans
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47557677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN00408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN00408A publication Critical patent/IN2014CN00408A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN408CHN2014 2011-07-19 2012-07-11 IN2014CN00408A (en:Method)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509397P 2011-07-19 2011-07-19
EP11174578 2011-07-19
PCT/EP2012/063552 WO2013010868A1 (en) 2011-07-19 2012-07-11 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors

Publications (1)

Publication Number Publication Date
IN2014CN00408A true IN2014CN00408A (en:Method) 2015-04-03

Family

ID=47557677

Family Applications (1)

Application Number Title Priority Date Filing Date
IN408CHN2014 IN2014CN00408A (en:Method) 2011-07-19 2012-07-11

Country Status (38)

Country Link
US (7) US9290504B2 (en:Method)
EP (4) EP2734522B1 (en:Method)
JP (6) JP5826931B2 (en:Method)
KR (2) KR101802689B1 (en:Method)
CN (2) CN103889987B (en:Method)
AU (4) AU2012285987C1 (en:Method)
BR (1) BR112014001255B1 (en:Method)
CA (1) CA2841886C (en:Method)
CL (1) CL2014000130A1 (en:Method)
CO (1) CO6940411A2 (en:Method)
CR (1) CR20140030A (en:Method)
CY (2) CY2021010I1 (en:Method)
DK (2) DK3689878T3 (en:Method)
DO (1) DOP2014000008A (en:Method)
EA (2) EA037644B1 (en:Method)
EC (1) ECSP14013217A (en:Method)
ES (3) ES2950569T3 (en:Method)
GT (1) GT201400009A (en:Method)
HR (2) HRP20212021T1 (en:Method)
HU (3) HUE056249T2 (en:Method)
IL (3) IL230511B (en:Method)
IN (1) IN2014CN00408A (en:Method)
LT (1) LT2734522T (en:Method)
MA (1) MA35348B1 (en:Method)
MX (1) MX342983B (en:Method)
MY (1) MY192354A (en:Method)
PE (1) PE20141681A1 (en:Method)
PH (2) PH12014500148A1 (en:Method)
PL (2) PL2734522T3 (en:Method)
PT (1) PT3689878T (en:Method)
RS (2) RS58177B1 (en:Method)
SG (1) SG10201605913VA (en:Method)
SI (2) SI2734522T1 (en:Method)
SM (2) SMT201900029T1 (en:Method)
TN (1) TN2014000027A1 (en:Method)
UA (1) UA115312C2 (en:Method)
WO (1) WO2013010868A1 (en:Method)
ZA (1) ZA202109164B (en:Method)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101113A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA3007788C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2012158764A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
IN2014CN00408A (en:Method) 2011-07-19 2015-04-03 Merck Sharp & Dohme
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
ES2731833T3 (es) 2012-09-10 2019-11-19 Principia Biopharma Inc Compuestos pirazolopirimidínicos comos inhibidores de cinasas
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
CA2887465A1 (en) * 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105682658B (zh) * 2013-05-30 2022-04-05 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
RU2712220C2 (ru) 2013-07-31 2020-01-27 Мерк Патент Гмбх Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
CN106456652B (zh) 2014-02-21 2020-09-11 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015193740A2 (en) * 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
AU2015296215A1 (en) * 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201609099A (zh) * 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016055982A1 (en) * 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
WO2016106629A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106627A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106626A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016128912A1 (en) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
US20180015079A1 (en) 2015-03-25 2018-01-18 National Cancer Center Therapeutic agent for bile duct cancer
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
ES2946489T3 (es) 2015-07-02 2023-07-19 Acerta Pharma Bv Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CN108602827B (zh) * 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
KR102486722B1 (ko) 2015-12-17 2023-01-11 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료제
EP3402503B1 (en) 2016-01-13 2020-10-21 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
JP7129704B2 (ja) 2016-06-29 2022-09-02 プリンシピア バイオファーマ インコーポレイテッド ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペント－２－エネニトリルの放出調節製剤
WO2018001331A1 (zh) * 2016-06-30 2018-01-04 杭州华东医药集团新药研究院有限公司 一种咪唑吡啶胺苯基衍生物及其用途
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
JP6737952B2 (ja) * 2016-08-17 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． チロシンキナーゼ活性を阻害するための縮合二環式化合物
WO2018064797A1 (zh) * 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
MX388457B (es) * 2016-12-21 2025-03-20 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
WO2018115965A1 (en) 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN106588937B (zh) * 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
US20190376971A1 (en) 2017-01-19 2019-12-12 Acerta Pharma B.V. Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
CN106831787B (zh) * 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
CN110312723B (zh) * 2017-02-20 2022-02-11 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
EP3585789A1 (en) 2017-02-24 2020-01-01 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
US10370381B2 (en) 2017-02-24 2019-08-06 Gilead Sciences, Inc. Inhibitors of bruton'S tyrosine kinase
WO2018175512A1 (en) * 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Bruton's tyrosine kinase inhibitors
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
US10800787B2 (en) 2017-04-20 2020-10-13 Apotex Inc. Process for the preparation of acalabrutinib
US10717740B2 (en) 2017-06-13 2020-07-21 Dr. Reddy's Laboratories Limited. Solid forms of acalabrutinib and process for preparation thereof
CN107522701B (zh) * 2017-09-01 2019-11-08 苏州富士莱医药股份有限公司 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
CN107602564B (zh) * 2017-09-20 2019-08-30 南京亘泰医药技术有限公司 布鲁顿酪氨酸激酶抑制剂
BR112020005039A2 (pt) 2017-09-25 2020-09-15 Astrazeneca Ab combinação de um inibidor de btk e um inibidor de cdk9 para tratar câncer
CN109836416B (zh) * 2017-11-27 2023-02-03 苏州鹏旭医药科技有限公司 一种化合物的制备方法
US11161851B2 (en) 2017-11-06 2021-11-02 Suzhou Pengxu Pharmatech Co. Ltd. Processes to produce acalabrutinib
JP2021510149A (ja) * 2018-01-05 2021-04-15 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド アカラブルチニブの新規結晶形及びその製造方法並びに用途
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
CN110256438B (zh) * 2018-03-12 2020-07-17 新发药业有限公司 一种阿可替尼的制备方法
EP3777860A4 (en) 2018-03-28 2021-12-15 Eisai R&D Management Co., Ltd. THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
TW202014184A (zh) 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
WO2019239374A1 (en) 2018-06-13 2019-12-19 Acerta Pharma B.V. Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
WO2019246176A1 (en) 2018-06-19 2019-12-26 Regeneron Pharmaceuticals, Inc. Anti-factor xii/xiia antibodies and uses thereof
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
BR112021003480A2 (pt) * 2018-08-29 2021-05-18 Acerta Pharma B.V. processos para a preparação de 4-{8-amino-3-[(2s)-1-(but-2-inoil)-pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)-benzamida
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
EP3830091A1 (en) 2018-09-25 2021-06-09 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
CN109020977B (zh) * 2018-10-26 2020-11-13 安庆奇创药业有限公司 一种Acalabrutinib的制备方法
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CN111377928A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种制备Acalabrutinib的方法
CN111377929A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种可用于治疗白血病阿卡替尼(Acalabrutinib)制备的方法
CN113365631B (zh) 2019-01-18 2024-08-30 杭州邦顺制药有限公司 布鲁顿酪氨酸激酶抑制剂
CA3131386A1 (en) * 2019-02-27 2020-09-03 Richard Keenan Imidazolopyrazine compounds for ire1 inhibition
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020198429A1 (en) 2019-03-27 2020-10-01 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
CN110563733A (zh) * 2019-09-12 2019-12-13 安帝康（无锡）生物科技有限公司 作为选择性btk抑制剂的咪唑并吡嗪类化合物
CA3154257A1 (en) 2019-10-14 2021-04-22 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
MX2022005250A (es) 2019-11-04 2022-06-08 Astrazeneca Ab Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
PH12022553376A1 (en) 2020-06-19 2024-03-25 Acerta Pharma Bv Acalabrutinib maleate dosage forms
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
CN113264938B (zh) * 2021-07-21 2021-11-02 北京鑫开元医药科技有限公司 一种咪唑并[1,5-a]吡嗪-8-胺类化合物、制备方法、药物组合物和应用
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2025125383A1 (en) 2023-12-11 2025-06-19 Synthon B.V. Crystalline forms of acalabrutinib hydrogen maleate
US12414950B1 (en) 2024-05-21 2025-09-16 Telios Pharma Inc. Methods of treating indolent systemic mastocytosis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085824A (ko) 1998-09-18 2001-09-07 스타르크, 카르크 단백질 키나아제 억제제로서의 피롤로피리미딘
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60037455T2 (de) 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
EP2305682A1 (en) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
HRP20110553T1 (hr) 2005-11-17 2011-09-30 Osi Pharmaceuticals FUZIONIRANI BICIKLIČKI INHIBITORI mTOR
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
PT2529622T (pt) 2006-09-22 2018-04-24 Pharmacyclics Llc Inibidores de tirosina cinase de bruton
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CA2708149A1 (en) 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2009126691A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102918042B (zh) * 2010-02-08 2016-03-09 默沙东有限责任公司 8-甲基-1-苯基-咪唑[1,5-a]吡嗪化合物
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
HRP20161027T1 (hr) 2010-05-31 2016-11-04 Ono Pharmaceutical Co., Ltd. Derivat purinona kao inhibitor btk kinaze
CA3007788C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
KR102052670B1 (ko) 2011-05-17 2019-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키나아제 저해제
US20130178483A1 (en) 2011-06-28 2013-07-11 Pharmacyclics, Inc. Methods and Compositions for Inhibition of Bone Resorption
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
IN2014CN00408A (en:Method) 2011-07-19 2015-04-03 Merck Sharp & Dohme
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US20140155406A1 (en) 2011-07-19 2014-06-05 Petrus Antonius De Adrianus Man 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk inhibitors
JP6506555B2 (ja) 2011-10-19 2019-04-24 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
MX2015011733A (es) 2013-03-14 2016-04-25 Pharmacyclics Llc Combinaciones de inhibidores de la tirosina quinasa de bruton e inhibidores de cyp3a4.
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
AU2014251028A1 (en) 2013-04-08 2015-11-05 Janssen Pharmaceutica Nv Ibrutinib combination therapy
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)

Also Published As

Publication number Publication date
ES2950569T3 (es) 2023-10-11
US20160159810A1 (en) 2016-06-09
CL2014000130A1 (es) 2014-08-22
SG10201605913VA (en) 2016-09-29
US10934296B2 (en) 2021-03-02
HUS2100012I1 (hu) 2021-05-28
MX342983B (es) 2016-10-19
JP6251220B2 (ja) 2017-12-20
JP2022088618A (ja) 2022-06-14
CO6940411A2 (es) 2014-05-09
ZA202109164B (en) 2025-04-30
DOP2014000008A (es) 2014-04-30
CR20140030A (es) 2014-06-03
MA35348B1 (fr) 2014-08-01
BR112014001255B1 (pt) 2019-07-02
NZ716110A (en) 2017-07-28
SMT202100729T1 (it) 2022-01-10
JP2018035184A (ja) 2018-03-08
EP3495368B1 (en) 2023-05-31
GT201400009A (es) 2017-09-28
DK3689878T3 (da) 2021-11-08
AU2017279778A1 (en) 2018-01-25
US20210230166A1 (en) 2021-07-29
EA201992270A3 (ru) 2020-03-31
EP3689878A1 (en) 2020-08-05
US9758524B2 (en) 2017-09-12
CY2021010I2 (el) 2021-06-25
CY1125613T1 (el) 2024-02-16
PH12014500148A1 (en) 2014-03-31
EP4249076A3 (en) 2023-11-01
MX2014000746A (es) 2014-05-07
US9790226B2 (en) 2017-10-17
IL291489A (en) 2022-05-01
US20140155385A1 (en) 2014-06-05
CN106243113A (zh) 2016-12-21
CN103889987B (zh) 2016-09-14
KR101702727B1 (ko) 2017-02-06
BR112014001255A2 (pt) 2017-02-21
US20160151364A1 (en) 2016-06-02
CA2841886A1 (en) 2013-01-24
EP2734522A1 (en) 2014-05-28
KR101802689B1 (ko) 2017-11-28
EP3495368A1 (en) 2019-06-12
HRP20190135T1 (hr) 2019-03-22
EP3689878B1 (en) 2021-10-06
LT2734522T (lt) 2019-02-11
HRP20212021T1 (hr) 2022-04-01
KR20160117642A (ko) 2016-10-10
IL266894B (en) 2022-04-01
AU2017279778B2 (en) 2019-09-19
SMT201900029T1 (it) 2019-02-28
DK2734522T3 (en) 2019-02-18
JP2019108395A (ja) 2019-07-04
EA201490300A1 (ru) 2014-05-30
NZ620085A (en) 2016-05-27
EA034558B1 (ru) 2020-02-20
AU2019275591A1 (en) 2020-01-02
AU2012285987A1 (en) 2014-02-06
EA037644B1 (ru) 2021-04-26
EP2734522B1 (en) 2018-10-31
CY2021010I1 (el) 2021-06-25
PE20141681A1 (es) 2014-11-14
ES2708224T3 (es) 2019-04-09
KR20140036324A (ko) 2014-03-25
US9290504B2 (en) 2016-03-22
US20180179212A1 (en) 2018-06-28
PH12017500166A1 (en) 2017-09-04
US20190276456A1 (en) 2019-09-12
AU2012285987B2 (en) 2016-03-10
EA201992270A2 (ru) 2020-01-16
JP6617130B2 (ja) 2019-12-11
IL266894A (en) 2019-07-31
MY192354A (en) 2022-08-17
JP6749444B2 (ja) 2020-09-02
AU2016203837A1 (en) 2016-06-30
JP5826931B2 (ja) 2015-12-02
UA115312C2 (uk) 2017-10-25
PT3689878T (pt) 2022-01-05
RS62760B1 (sr) 2022-01-31
ECSP14013217A (es) 2015-03-31
PH12017500166B1 (en) 2018-10-26
ES2904707T3 (es) 2022-04-05
IL230511B (en) 2019-05-30
HUE056249T2 (hu) 2022-02-28
CN103889987A (zh) 2014-06-25
PL2734522T3 (pl) 2019-04-30
AU2016203837B2 (en) 2018-01-25
EP4249076A2 (en) 2023-09-27
PL3689878T3 (pl) 2022-02-14
JP2020189865A (ja) 2020-11-26
CN106243113B (zh) 2018-12-18
US20230331729A1 (en) 2023-10-19
US10239883B2 (en) 2019-03-26
HUE041987T2 (hu) 2019-06-28
JP7054721B2 (ja) 2022-04-14
SI3689878T1 (sl) 2021-12-31
WO2013010868A1 (en) 2013-01-24
RS58177B1 (sr) 2019-03-29
TN2014000027A1 (en) 2015-07-01
AU2012285987C1 (en) 2016-09-08
SI2734522T1 (sl) 2019-03-29
IL230511A0 (en) 2014-03-31
JP2014520870A (ja) 2014-08-25
AU2019275591B2 (en) 2020-10-01
JP2016034968A (ja) 2016-03-17
CA2841886C (en) 2016-08-16

Similar Documents

Publication Publication Date Title
ZA202109164B (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
IN2014DN09352A (en:Method)
IN2014DN09348A (en:Method)
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MD20150023A2 (ro) Piridinone biciclice noi
NZ763816A (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
WO2016109217A3 (en) Btk inhibitors
PH12015502365A1 (en) Bace1 inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
IN2014DN09347A (en:Method)
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
CY1121174T1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4-ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
IN2013MU01239A (en:Method)
IN2013MU01243A (en:Method)
IN2013MU01241A (en:Method)